Rudradip Das

About

Dr. Rudradip Das is a passionate medicinal chemist with a robust academic background and extensive research experience. After earning a B.Pharm degree from West Bengal University of Technology (2017) and a Master’s in Medicinal Chemistry from NIPER SAS Nagar (2019), Dr. Rudradip Das completed a Ph.D. at NIPER Ahmedabad under the mentorship of Dr. Amit Shard. During their Ph.D., their research focused on designing and synthesizing innovative PKM2 modulators for cancer therapy. Currently, as a Post-doctoral fellow at IOCB Prague, Dr. Rudradip Das is exploring the development of novel methyl transferase inhibitors, working within the Drug Development and Medicinal Chemistry group led by Dr. Radim Nencka. With a keen interest in advancing therapeutic solutions, Dr. Rudradip Das is committed to driving forward the frontiers of drug discovery.

Employment

• GITAM University Hyderabad Assistant Professor
  2026 - Present
• Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry Post-doctoral Fellow
  2024 - 2026

Education

• National Institute of Pharmaceutical Education and Research Ahmedabad Gujarat IN Ph.D.
  2019 - Present
• National Institute of Pharmaceutical Education and Research Master in Science (Pharm)
  2017 - 2019
• West Bengal University of Technology Bachelor in Pharmacy (B.Pharm)
  2013 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• 2,5-Diazabicyclo[2.2.1]heptane in medicinal chemistry: a treasure trove of therapeutic opportunities
  RSC Medicinal Chemistry 2026 DOI: 10.1039/D5MD00992H
  +Save
• Integrative QSAR strategies for hexokinase 2 (HK2) targeting: combining ligand-based, structure-based, and AI-enabled drug discovery
  In Silico Research in Biomedicine 2026 DOI: 10.1016/j.insi.2026.100482
  +Save
• Comprehensive exploration of novel imidazopyrimidine derivatives: Design, synthesis, computational assessment, and anti-breast cancer activity
  Journal of Molecular Structure 2025 DOI: 10.1016/j.molstruc.2024.141062
  +Save
• Modulation of the LIMK Pathway by Myricetin: A Protective Strategy Against Neurological Impairments in Spinal Cord Injury
  Neurospine 2024 DOI: 10.14245/ns.2448546.273
  +Save
• Novel sulfonamides unveiled as potent anti-lung cancer agents via tumor pyruvate kinase M2 activation
  RSC Medicinal Chemistry 2024 DOI: 10.1039/D4MD00367E
  +Save
• Objective assessment of adrenocortical carcinoma driver genes and their correlation with tumor pyruvate kinase M2
  Gene 2022 DOI: 10.1016/j.gene.2022.146354
  +Save
• A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics
  Drug Discovery Today 2021 DOI: 10.1016/j.drudis.2021.12.009
  +Save
• Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer’s Disease
  Central Nervous System Agents in Medicinal Chemistry 2021 DOI: 10.2174/1871524920666201021164805
  +Save
• Efficient Green Protocols for the Preparation of Pyrazolopyrimidines
  ChemistrySelect 2021 DOI: 10.1002/slct.202101298
  +Save
• Design and in-silico screening of Peptide Nucleic Acid (PNA) inspired novel pronucleotide scaffolds targeting COVID-19.
  Current computer-aided drug design 2020 DOI: 10.2174/1573409916666200923143935
  +Save